Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of weekly intravenous Alpha1-Proteinase Inhibitor (Human), Modified in AATD
2015-004110-23Phase 3Active
- Sponsor
- Grifols
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alpha1-proteinase inhibitor in alpha-1 antitrypsin deficiency emphysema, sponsored by Grifols. Primary endpoint: Safety (adverse events and laboratory parameters). Started Jan 2016; status: active.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency emphysema
Beyond the preview
Go deeper on 2015-004110-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004110-23.